AlloVir (ALVR) Stock Price, News & Analysis

Company Overview

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Key Stats

• Today's Range: $3.15 to $3.44
• 50-Day Range: $3.25 to $11.47
• 52-Week Range: $7.96 to $24.15
• Volume: 59,581 shs
• Average Volume: 16,299 shs
• Market Capitalization: $16.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ALVR Stock Analysis - Frequently Asked Questions

How have ALVR shares performed this year?

AlloVir's stock was trading at $9.66 at the beginning of the year. Since then, ALVR shares have decreased by 65.5% and is now trading at $3.33.
View the best growth stocks for 2025 here.

How were AlloVir's earnings last quarter?

AlloVir, Inc. (NASDAQ:ALVR) announced its quarterly earnings data on Wednesday, August, 14th. The company reported ($1.15) earnings per share for the quarter, beating analysts' consensus estimates of ($2.30) by $1.15.

When did AlloVir's stock split?

Shares of AlloVir reverse split before market open on Thursday, January 16th 2025. The 1-23 reverse split was announced on Wednesday, January 15th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did AlloVir IPO?

AlloVir (ALVR) raised $252 million in an initial public offering (IPO) on Thursday, July 30th 2020. The company issued 14,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO.

How do I buy shares of AlloVir?

Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AlloVir own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AlloVir investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 5/21/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALVR
• CIK: 1754068
• Web: www.allovir.com
• Phone: 617-433-2605
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($20.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-190,420,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -71.03%
• Return on Assets: -61.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 86.78
• Quick Ratio: 86.78

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $29.35 per share
• Price / Book: 0.11

Miscellaneous

• Outstanding Shares: 5,043,000
• Free Float: 3,425,000
• Market Cap: $16.79 million
• Optionable: Optionable
• Beta: 0.63